FY2025 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Investment analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other brokerages have also recently issued reports on IMUX. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Immunic in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $1.20 on Wednesday. The company has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.21. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The firm has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.89.

Institutional Trading of Immunic

A number of institutional investors have recently bought and sold shares of IMUX. Millennium Management LLC lifted its stake in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC increased its holdings in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after buying an additional 96,894 shares during the period. Barclays PLC bought a new position in shares of Immunic during the 4th quarter worth approximately $84,000. Finally, HB Wealth Management LLC acquired a new stake in shares of Immunic during the 4th quarter worth approximately $81,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.